Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies : a national retrospective study on the behalf of G2I and Intergroupe Francophone du Myélome
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Bispecific antibodies (BsAbs) are an effective treatment used in relapsed or refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events appear to be frequent in clinical trials. Real-world data on epidemiology, characteristics, risk factors, and outcomes of infections in patients treated with BsAb are still needed.
METHODS: A retrospective, multicentre study in BsAb-treated patients with multiple myeloma was performed in 14 French centres from December 2020 to February 2023. The primary objective was to describe the incidence of infections that required hospitalization, specific treatment, or adaptation in BsAb administration.
RESULTS: Among 229 patients with multiple myeloma treated with BsAb, 153 (67%) received teclistamab, 47 (20%) received elranatamab, and 29 (13%) talquetamab. We reported a total of 234 infections, including 123 (53%) of grade of ≥3. Predominant infections affected the respiratory tract (n = 116, 50%) followed by bacteraemias (n = 36, 15%). The hospitalization rate was 56% (n = 131), and 20 (9%) infections resulted in death. Global cumulative incidence of the first infection was 70% in all patients, 73% in patients treated with B-cell maturation antigen-targeting, and 51% with GPRC5D-targeting BsAb. In univariate analyses, corticosteroids for cytokine release syndrome (CRS)/immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with a higher risk of first infection (HR = 2.13; 95% CI, 1.38-3.28), whereas GPRC5D-targeting BsAb and anti-bacterial prophylaxis were associated with a lower risk (HR = 0.53; 95% CI, 0.3-0.94 and HR = 0.65; 95% CI, 0.46-0.9). Fine and Gray multivariate model found that only corticosteroids for CRS/ICANS were correlated with a higher risk of first infection (HR = 2.01; 95% CI, 1.27-3.19).
DISCUSSIONS: The implementation of preventive measures that aim to mitigate the risk of infection under BsAb is pivotal, notably in patients who received corticosteroids for CRS/ICANS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - (2024) vom: 01. März |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Adverse event |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.cmi.2024.02.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369223047 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369223047 | ||
| 003 | DE-627 | ||
| 005 | 20240322000358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2024.02.023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369223047 | ||
| 035 | |a (NLM)38432433 | ||
| 035 | |a (PII)S1198-743X(24)00098-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jourdes, Aurélie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies |b a national retrospective study on the behalf of G2I and Intergroupe Francophone du Myélome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Bispecific antibodies (BsAbs) are an effective treatment used in relapsed or refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events appear to be frequent in clinical trials. Real-world data on epidemiology, characteristics, risk factors, and outcomes of infections in patients treated with BsAb are still needed | ||
| 520 | |a METHODS: A retrospective, multicentre study in BsAb-treated patients with multiple myeloma was performed in 14 French centres from December 2020 to February 2023. The primary objective was to describe the incidence of infections that required hospitalization, specific treatment, or adaptation in BsAb administration | ||
| 520 | |a RESULTS: Among 229 patients with multiple myeloma treated with BsAb, 153 (67%) received teclistamab, 47 (20%) received elranatamab, and 29 (13%) talquetamab. We reported a total of 234 infections, including 123 (53%) of grade of ≥3. Predominant infections affected the respiratory tract (n = 116, 50%) followed by bacteraemias (n = 36, 15%). The hospitalization rate was 56% (n = 131), and 20 (9%) infections resulted in death. Global cumulative incidence of the first infection was 70% in all patients, 73% in patients treated with B-cell maturation antigen-targeting, and 51% with GPRC5D-targeting BsAb. In univariate analyses, corticosteroids for cytokine release syndrome (CRS)/immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with a higher risk of first infection (HR = 2.13; 95% CI, 1.38-3.28), whereas GPRC5D-targeting BsAb and anti-bacterial prophylaxis were associated with a lower risk (HR = 0.53; 95% CI, 0.3-0.94 and HR = 0.65; 95% CI, 0.46-0.9). Fine and Gray multivariate model found that only corticosteroids for CRS/ICANS were correlated with a higher risk of first infection (HR = 2.01; 95% CI, 1.27-3.19) | ||
| 520 | |a DISCUSSIONS: The implementation of preventive measures that aim to mitigate the risk of infection under BsAb is pivotal, notably in patients who received corticosteroids for CRS/ICANS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse event | |
| 650 | 4 | |a Bispecific antibodies | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Infections | |
| 650 | 4 | |a Multicentric | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Retrospective | |
| 700 | 1 | |a Cellerin, Elise |e verfasserin |4 aut | |
| 700 | 1 | |a Touzeau, Cyrille |e verfasserin |4 aut | |
| 700 | 1 | |a Harel, Stéphanie |e verfasserin |4 aut | |
| 700 | 1 | |a Denis, Blandine |e verfasserin |4 aut | |
| 700 | 1 | |a Escure, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Faure, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Jamard, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Danion, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Sonntag, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Ader, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Karlin, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a Soueges, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Cazelles, Clarisse |e verfasserin |4 aut | |
| 700 | 1 | |a de La Porte des Vaux, Clémentine |e verfasserin |4 aut | |
| 700 | 1 | |a Frenzel, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Lanternier, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Brousse, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Cazaubiel, Titouan |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Collignon, Aude |e verfasserin |4 aut | |
| 700 | 1 | |a Blot, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Pieragostini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Charles, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Chaleteix, Carine |e verfasserin |4 aut | |
| 700 | 1 | |a Redor, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Roland, Virginie |e verfasserin |4 aut | |
| 700 | 1 | |a Cartau, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Macro, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Chalopin, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Vallet, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Perrot, Aurore |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Blondel, Guillaume |e verfasserin |4 aut | |
| 700 | 0 | |a G2I and the IFM networks |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g (2024) vom: 01. März |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:01 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2024.02.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 01 |c 03 | ||